| Document |
Document Title |
|
WO/2024/051766A1 |
The present disclosure relates to a compound of formula (I) or a salt, an enantiomer, a diastereomer, an isotope-enriched analogue, a solvate, a prodrug or a polymorph thereof, and the use thereof. Further provided in the present disclos...
|
|
WO/2024/049159A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2024/049067A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2024/044847A1 |
The present application relates to methods of activating serotonin receptors in a cell using indoline derivatives of general Formula (I) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, as well as to treating diseas...
|
|
WO/2024/047135A1 |
Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.
|
|
WO/2024/046409A1 |
The present invention relates to a heterocyclic compound, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention relates to a heterocyclic compound as shown in general formula (I), a preparat...
|
|
WO/2024/045747A1 |
The present application belongs to the technical field of organic materials, and provides an organic compound, an electronic component and an electronic device. The structure of the organic compound is as shown in formula (1), and there ...
|
|
WO/2024/046253A1 |
Provided in the present invention are a sodium channel regulator and the use thereof. The sodium channel regulator of the present invention has a brand-new structure and has an excellent in-vitro inhibitory effect on Nav 1.8. The compoun...
|
|
WO/2024/044848A1 |
The present application relates to indazole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
|
WO/2024/041609A1 |
The present invention relates to a benzo bicyclic compound and use thereof in a medicament, and specifically relates to a novel benzo bicyclic compound and a pharmaceutical composition comprising the compound. The present invention also ...
|
|
WO/2024/044667A2 |
Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and/or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for trea...
|
|
WO/2024/043334A1 |
The present invention addresses the problem of providing a compound and pharmaceutical composition that possesses inhibitory activity against the drug efflux pumps of drug-resistant bacteria and, when used in combination with another dru...
|
|
WO/2024/043703A1 |
The present invention relates to a novel compound and an organic light-emitting device comprising same.
|
|
WO/2024/044616A1 |
The present disclosure provides for polyfunctionalized biaryls having complex biaryl architectures, methods of making polyfunctionalized biaryls, and the like. The present disclosure provides for the cine-ipso-difunctionalization transfo...
|
|
WO/2024/040995A1 |
The present application relates to a synthesis method for an N-methyl-3-substituted methyl-4-pyrazolecarboxamide derivative and N-methyl-3-substituted methyl-4-pyrazolecarboxylic acid, the method comprising the following steps: S1: synth...
|
|
WO/2024/042187A1 |
Disclosed herein are compounds of the formula (I) or a pharmaceutically acceptable salt thereof (I) Wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3' and R3" independently represent a hydrogen atom, a met...
|
|
WO/2024/042152A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3' and R3" independently represent a hydrogen atom, a methyl...
|
|
WO/2024/044757A1 |
The present disclosure provides compounds and compositions that are useful as MYC protein modulators and methods of using the same for treating MYC-mediated diseases or disorders.
|
|
WO/2024/041503A1 |
The present invention discloses compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are processes for ...
|
|
WO/2024/039689A1 |
Provided herein are compounds of formula (I) that modulate RMB39 and methods of using the compounds in RMB39-associated disorders, such as cancer (e.g., renal cell carcinoma).
|
|
WO/2024/037520A1 |
Disclosed in the present invention are a new compound as represented by general formula I, a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer and a racemate thereof, and a pharmaceutical composition containing the compo...
|
|
WO/2024/037073A1 |
The present application belongs to the technical field of organic materials, and relates to a nitrogen-containing compound, an electronic element and an electronic device. The compound has a structure as shown in formula (1) below. The n...
|
|
WO/2024/035123A1 |
The present specification provides a heterocyclic compound, an organic light-emitting device comprising same, and a composition for an organic layer of an organic light-emitting device.
|
|
WO/2024/033293A1 |
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
|
|
WO/2024/036176A1 |
Provided herein are heterocyclic compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. The subject compounds and compositions are useful for the treatment...
|
|
WO/2024/036170A1 |
Provided herein are heterocyclic compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. The subject compounds and compositions are useful for the treatment...
|
|
WO/2024/031089A1 |
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
|
|
WO/2024/030647A1 |
Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
|
|
WO/2024/029927A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2024/026536A1 |
The present disclosure relates to a compound of formula (I), or an N-oxide, pharmaceutically acceptable salt, prodrug or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compound. Th...
|
|
WO/2024/027723A1 |
Disclosed in the present invention are a crystal form, a salt type and a composition of a pyridazine compound and a preparation method therefor, and specifically disclosed are a method for preparing a crystal form A and a composition of ...
|
|
WO/2024/030633A1 |
Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
|
|
WO/2024/026540A1 |
Disclosed are compounds of Formula I and their use as inhibitors of the viral protease non-structural protein 5 (NSP5). Typically, the NSP5 is derived from a coronavirus, more typically from SARS-CoV-2. More particularly, the invention r...
|
|
WO/2024/024726A1 |
Provided is a compound represented by formula (1).
|
|
WO/2024/022490A1 |
The present application provides a substituted phenylethylamine-triazine compound, a method for preparing same and use thereof, and a herbicide. The substituted phenylethylamine-triazine compound has a structure represented by formula (I...
|
|
WO/2024/025151A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...
|
|
WO/2024/026290A1 |
The present invention relates to compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions of the compounds, or salts thereof, that can inhibit secreted phospholipases A2 (sPLA2-X) enzymes, wherein th...
|
|
WO/2024/023332A1 |
The invention relates to novel silicon-based fluoride acceptor groups (SiFA groups) of the following formulae (Ia, Ib, Ic) as well as to compounds suitable for use in radiopharmacy comprising such groups, wherein R1 and R2 are each a lin...
|
|
WO/2024/025364A1 |
The present specification relates to a heterocyclic compound, an organic light-emitting element, and a composition for an organic material layer of an organic light-emitting element.
|
|
WO/2024/025353A1 |
The present invention relates to: an organic compound employed as an organic layer material, such as an electron-blocking layer in an organic light-emitting device; and an organic light-emitting device comprising same. When the compound ...
|
|
WO/2024/016687A1 |
The present application belongs to the field of organic light-emitting materials, and particularly relates to a nitrogen-containing compound, an electronic element and an electronic apparatus. The structure of the nitrogen-containing com...
|
|
WO/2024/020379A2 |
Prodrugs including cleavable moieties capable of specific binding to a target are presented. Related pharmaceutical compositions and methods are also presented.
|
|
WO/2024/019661A1 |
The present disclosure concerns a method of promoting the ubiquitination of MK2 protein, comprising contacting the MK2 protein with a compound of Formula (I) or a salt, solvate, stereoisomer or prodrug thereof. The present disclosure als...
|
|
WO/2024/017897A1 |
The present invention relates to selective oxadiazole-based inhibitors of histone deacetylase 6 (HDAC6) and uses thereof in treating various diseases and disorders.
|
|
WO/2024/012551A1 |
The present invention relates to a class of deuterium-substituted pyridazine benzothiophene compounds and the use thereof.
|
|
WO/2024/014866A1 |
The present invention relates to a novel compound with excellent carrier transport ability, light emitting ability, and thermal stability, and an organic electroluminescent device that comprises the compound in at least one organic mater...
|
|
WO/2024/014716A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for an organic layer.
|
|
WO/2024/014813A1 |
The present invention relates to an organic compound and an organic light-emitting device comprising same in an organic layer of the device, in which the organic compound is employed as a host material for a light-emitting layer in an or...
|
|
WO/2024/014932A1 |
The present invention relates to: a compound for an organic optoelectronic diode, represented by chemical formula 1; and an organic optoelectronic diode and a display device, which comprise same. The details of chemical formula 1 are the...
|
|
WO/2024/012522A1 |
Provided are a carbazole derivative and a use thereof in an organic light-emitting diode (OLED). The carbazole derivative has a fused carbazole structure, has a high triplet energy level, and increases conjugation of a carbazole parent n...
|
